Prax 222 (elsunersen) Phase II initial results.
HTML-код
- Опубликовано: 31 янв 2025
- Watch a recent presentation by Marcio Souza, CEO of Praxis Precision Medicines provides an update of the Prax 222 (elsunersen). This ASO program for Gain of Function presentation has been dosed in 5 patients now with initial results looking promising.
#SCN2A #cureSCN2A #ASO #raredisease